ITRM-- Iterum Therapeutics

Discussion in 'Stock Message Boards NYSE, NASDAQ, AMEX' started by Biotechmaster, Oct 24, 2019.

  1. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    293
    Likes Received:
    10
    Market cap $51 M --Cash $52 M --3x Phase 3 readouts (potential Blockbuster) are imminent (during this quarter) ..Completely undiscovered ultra low float gem with significant upside potential

    Iterum (ITRM)

    Marktkap $51 M
    Cash: $52 M
    Price: $3.53

    Shares Out 14.4 M


    “The second quarter was marked by continued progress in our three pivotal Phase 3 clinical trials of sulopenem,” said Corey Fishman, Chief Executive Officer of Iterum Therapeutics plc. “Based on current enrollment rates, we anticipate topline data from the complicated intra-abdominal (cIAI) and the complicated urinary tract infection (cUTI) trials in the fourth quarter. This would allow us the flexibility to file our new drug applications (NDAs) in the first quarter of 2020."



    take a look what insiders paid for their shares
    http://openinsider.com/search?q=itrm


    New Presentation
    https://d1io3yog0oux5.cloudfront.ne...2669/pdf/Iterum+Company+Deck_October+2019.pdf


    major shareholders:

    Canaan Partners ...1.7M
    Sofinnova ...1.7M
    Frazier ...1.5M
    New Leaf Venture ...1.5M
    Arix Bioscience ...1.1M
    Pivotal ...945.1K
    Malik (Shahzad) ...868.2K
    Advent Venture ...868.2K
    Cormorant Asset ...396.4K
    Franklin ...351.6K



    [​IMG]


    [​IMG]

    [​IMG]
     

Share This Page